Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia
Gordon Ruan(Mayo Clinic in Arizona), Thomas E. Witzig(WinnMed), Vaishali Bhardwaj, Matthew J. Schellenberg(Mayo Clinic), Sameer A. Parikh(Mayo Clinic), Jithma P. Abeykoon(Mayo Clinic), Xiaosheng Wu(Mayo Clinic), Taylor L. Witter(Mayo Clinic), Michelle K. Manske(Mayo Clinic in Arizona), Kimberly Gwin(Mayo Clinic in Arizona), Kari G. Rabe(Mayo Clinic), Neil E. Kay(Mayo Clinic)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630